<DOC>
	<DOCNO>NCT02635334</DOCNO>
	<brief_summary>This pilot study effect montelukast subject asthma 65 year old old . Montelukast leukotriene receptor antagonist U.S. F.D.A . approve treatment asthma subject 12 month old older . This study do placebo control study montelukast focus group patient . Elderly asthmatic mostly ignore asthma study . They likely underdiagnosed , undertreated , hospitalized asthma compare young asthmatic . The pathophysiology asthma elderly typically different young patient . This double-blind , placebo-controlled , crossover study . Investigators plan enroll thirty subject diagnose asthma least one year , non smoker , smoke 10 pack/year tobacco product lifetime . After run-in period one week , study subject take montelukast 10 mg orally 8 week first placebo 8 week , vice versa . Primary objective study evaluate effect montelukast asthma symptom assess daily symptom score , Asthma Control Test number puff albuterol , spirometric value ( FEV1 ) . Secondary objective include study whether montelukast affect peripheral blood eosinophil count serum IgE level .</brief_summary>
	<brief_title>Asthma Elderly : The Effect Montelukast</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Asthma diagnose least one year ; Able swallow small capsule . Tobacco smoke 10/pack year ; Previous adverse reaction montelukast leukotriene inhibitor ; History hypereosinophilic disorder atopic disease ; Treatment montelukast within 4 week randomization ; Asthma exacerbation treatment prednisone/other systemic steroid within 4 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>